LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 109

Search options

  1. Book ; Online: New Developments in the Pathogenesis of Rheumatoid Arthritis

    Sakkas, Lazaros I

    2017  

    Keywords Immunology ; cytokines, microrna, biomarkers, epigenetics, microbiota, mirna
    Language English
    Size 1 electronic resource (164 pages)
    Publisher IntechOpen
    Document type Book ; Online
    Note English
    HBZ-ID HT030646484
    ISBN 9789535173427 ; 9535173421
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Book ; Online: Updates in the Diagnosis and Treatment of Vasculitis

    Sakkas, Lazaros I. / Katsiari, Christina

    2013  

    Keywords Immunology
    Size 1 electronic resource (284 pages)
    Publisher IntechOpen
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021049896
    ISBN 9789535170983 ; 9535170988
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  3. Article ; Online: Sex bias in immune response: it is time to include the sex variable in studies of autoimmune rheumatic diseases.

    Sakkas, Lazaros I / Chikanza, Ian C

    Rheumatology international

    2023  Volume 44, Issue 2, Page(s) 203–209

    Abstract: Healthy females and males differ in their immune cell composition and function and females generally mount stronger immune response than males and are much more susceptible to autoimmune rheumatic diseases. Females differ from males in sex hormones, and ... ...

    Abstract Healthy females and males differ in their immune cell composition and function and females generally mount stronger immune response than males and are much more susceptible to autoimmune rheumatic diseases. Females differ from males in sex hormones, and X-chromosome genes. Sex hormones affect immune cells and responses, and may induce epigenetic DNA changes. The importance of X-chromosome genes is exemplified in men with the Klinefelter syndrome (47,XXY) who have an additional X-chromosome and develop systemic lupus erythematosus(SLE) as frequently as women. X-chromosome contains genes critical for the immune response, such as FOXP3, toll-like receptor(TLR)7, TLR8, CD40 Ligand, IL2RG, IL9R, BTK, and others. Whereas one X-chromosome in females is randomly inactivated early in embryonic development, around 25% of X-linked genes escape inactivation and result in more X-linked gene dosage in females. We use two key female-biased autoimmune rheumatic diseases, SLE and systemic sclerosis, to review differences in immune response, and clinical manifestations between females and males. The inclusion of sex variable in research will facilitate precision medicine and optimal patient outcome.
    MeSH term(s) Male ; Humans ; Female ; Sexism ; Autoimmune Diseases/genetics ; Lupus Erythematosus, Systemic/genetics ; Rheumatic Diseases/genetics ; Gonadal Steroid Hormones
    Chemical Substances Gonadal Steroid Hormones
    Language English
    Publishing date 2023-09-16
    Publishing country Germany
    Document type Editorial
    ZDB-ID 8286-7
    ISSN 1437-160X ; 0172-8172
    ISSN (online) 1437-160X
    ISSN 0172-8172
    DOI 10.1007/s00296-023-05446-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Mediterranean Journal of Rheumatology September 2019 Issue Highlights.

    Sakkas, Lazaros I

    Mediterranean journal of rheumatology

    2019  Volume 30, Issue 3, Page(s) 139–140

    Language English
    Publishing date 2019-09-30
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.30.3.139
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Mediterranean Journal of Rheumatology June 2018 Issue Highlights.

    Sakkas, Lazaros I

    Mediterranean journal of rheumatology

    2018  Volume 29, Issue 2, Page(s) 65–66

    Language English
    Publishing date 2018-06-29
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.29.2.65
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Regulatory B cells in autoimmune rheumatic diseases.

    Sakkas, Lazaros I

    Mediterranean journal of rheumatology

    2017  Volume 28, Issue 2, Page(s) 75–79

    Abstract: Background: Regulatory B cells (regulatory B cells, Breg cells) in recent years have been shown to be important immunoregulatory factors.: Aim: To review the role of Breg cells in autoimmune rheumatic diseases.: Methods: This descriptional review ... ...

    Abstract Background: Regulatory B cells (regulatory B cells, Breg cells) in recent years have been shown to be important immunoregulatory factors.
    Aim: To review the role of Breg cells in autoimmune rheumatic diseases.
    Methods: This descriptional review was carried out after research on PubMed using the keywords "Bregs and rheumatoid arthritis", "systemic lupus erythematosus", "Sjögren's syndrome", "systemic sclerosis", "vasculitis", and "dermatomyositis".
    Results: Breg cells have an inhibitory effect on pro-inflammatory Th1 and Th17 cells and prevent the development of autoimmune diseases. Breg cells mediate their effects through interleukin-10 (IL-10, IL-10+Breg cells), but recently other Breg cells have been recognized that mediate their effects through IL-35 (IL-35+Breg cells), or through transforming growth factor-β (TGFβ, TGFβ+Breg cells). In experimental models of autoimmune diseases, Breg cells are decreased, and when expanded ex vivo and re-infused back into animals, they ameliorate disease. In humans, IL-10+Breg cells are decreased in active autoimmune diseases, such as rheumatoid arthritis, ANCA-associated vasculitis, and systemic sclerosis, and may increase to normal levels in disease remission.
    Conclusions: The deficiency of IL-10+Breg cells during active autoimmune rheumatic disease suggests that Breg cells may be used as biomarkers and be a possible therapeutic target in these diseases.
    Language English
    Publishing date 2017-06-27
    Publishing country Greece
    Document type Journal Article ; Review
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.28.2.75
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Mediterranean Journal of Rheumatology September 2017 Highlights.

    Sakkas, Lazaros I

    Mediterranean journal of rheumatology

    2017  Volume 28, Issue 3, Page(s) 110–111

    Language English
    Publishing date 2017-09-29
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.28.3.110
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A new player in psoriatic arthritis: a JAK inhibitor.

    Sakkas, Lazaros I

    Mediterranean journal of rheumatology

    2017  Volume 28, Issue 4, Page(s) 210–211

    Language English
    Publishing date 2017-12-22
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.28.4.210
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis’ disease activity indicators: a systematic review and meta-analysis of randomized placebo-controlled trials

    Gkiouras, Konstantinos / Grammatikopoulou, Maria G. / Myrogiannis, Ioannis / Papamitsou, Theodora / Rigopoulou, Eirini I. / Sakkas, Lazaros I. / Bogdanos, Dimitrios P.

    Critical Reviews in Food Science and Nutrition. 2024 Jan. 2, v. 64, no. 1 p.16-30

    2024  

    Abstract: Theoretical evidence and previous studies suggest that oralnutrient supplementation (ONS) with n-3 fatty acids for rheumatoid arthritis (RA) has the potential to lower disease activity indicators and non-steroidal anti-inflammatory drug (NSAID) uptake. A ...

    Abstract Theoretical evidence and previous studies suggest that oralnutrient supplementation (ONS) with n-3 fatty acids for rheumatoid arthritis (RA) has the potential to lower disease activity indicators and non-steroidal anti-inflammatory drug (NSAID) uptake. A systematic search was conducted on five databases/registries from inception until May 23, 2021 with the aim to identify randomized placebo-controlled trials comparing n-3 supplements to placebo on disease-specific outcomes. A total of 23 studies matched the criteria (PROSPERO: CRD42019137041). Pooled analyses revealed that n-3 ONS provided a small effect in reducing pain [standardized mean difference (SMD): −0.16, 95% confidence intervals (CI): −0.40 to 0.09], and tender (SMD: −0.20, 95% CI: −0.46 to 0.05) and swollen joint count (SMD: −0.10, 95% CI: −0.28 to 0.07). In sensitivity analyses, there was a small effect in the reduction of NSAIDs intake (SMD: −0.22, 95% CI: −0.90 to 0.46), and c-reactive protein was reduced only by 0.21 mg/dL (95% CI: −0.75 to 0.33). Similar findings were observed regarding other objective/subjective outcomes. The certainty of the evidence was mostly of “very low/low” quality. Overall, n-3 ONS in RA might have a limited clinical benefit. Previous findings suggesting a reduction in NSAID intake may have been biased from the inadequate blinding of interventions.
    Keywords C-reactive protein ; food science ; meta-analysis ; nonsteroidal anti-inflammatory agents ; nutrition ; omega-3 fatty acids ; pain ; placebos ; rheumatoid arthritis ; systematic review ; Autoimmune disease ; rheumatic disease ; docosahexaenoic acid ; eicosapentaenoic acid ; EPA ; DHA ; dietary supplements
    Language English
    Dates of publication 2024-0102
    Size p. 16-30.
    Publishing place Taylor & Francis
    Document type Article ; Online
    ZDB-ID 1037504-1
    ISSN 1549-7852 ; 1040-8398
    ISSN (online) 1549-7852
    ISSN 1040-8398
    DOI 10.1080/10408398.2022.2104210
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article ; Online: Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.

    Sakkas, Lazaros I

    Drug design, development and therapy

    2016  Volume 10, Page(s) 2723–2728

    Abstract: Systemic sclerosis (SSc) is a multisystem disease characterized by extensive collagen deposition in skin and internal organs, fibrointimal microvasculopathy, and activation of the immune system. T cells and B cells can promote fibrosis in SSc. ... ...

    Abstract Systemic sclerosis (SSc) is a multisystem disease characterized by extensive collagen deposition in skin and internal organs, fibrointimal microvasculopathy, and activation of the immune system. T cells and B cells can promote fibrosis in SSc. Interleukin (IL)-6 is implicated in the pathogenesis of SSc. IL-6 is increased in the peripheral blood and lesional skin from patients with SSc, and induces fibroblast collagen production directly and indirectly by inducing profibrotic M2 macrophages. IL-6 also induces Th17 differentiation and promotes B cell differentiation toward Ig-producing plasma cells. IL-6 is also implicated in the pathogenesis of SSc in animal models as it is increased in mice with bleomycin-induced fibrosis, whereas neutralization of IL-6 in these mice prevents skin fibrosis. IL-6 acts on cells by binding to IL-6 receptor (IL-6R) which is transmembrane or soluble, and then recruits the signal-transducing glycoprotein 130 which is ubiquitously expressed. Tocilizumab is an anti-IL-6R humanized monoclonal antibody that blocks IL-6-mediated signaling. Tocilizumab has been approved for the treatment of moderate-to-severe rheumatoid arthritis, for polyarticular and systemic juvenile idiopathic arthritis, and for Castleman's disease, and is well tolerated. Case reports and a Phase II, randomized trial in SSc have shown some improvement of skin tightness and delayed deterioration of lung function. A Phase III randomized trial in SSc is anticipated.
    MeSH term(s) Animals ; Antibodies, Monoclonal, Humanized/therapeutic use ; Humans ; Interleukin-6/metabolism ; Scleroderma, Systemic/drug therapy ; Scleroderma, Systemic/metabolism
    Chemical Substances Antibodies, Monoclonal, Humanized ; Interleukin-6 ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2016
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S99696
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top